Ana Radeljevic
Directeur/Membre du Conseil chez MERRIMACK PHARMACEUTICALS, INC.
Postes actifs de Ana Radeljevic
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| MERRIMACK PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 06/06/2022 | - |
| Independent Dir/Board Member | 06/06/2022 | - | |
ADRx, Inc.
 ADRx, Inc. Pharmaceuticals: MajorHealth Technology ADRx, Inc. is a biopharmaceutical company. The firm advances drug candidates for Alzhiemer’s disease, systemic amyloidosis and ovarian cancer. The company was founded by Gary Wilcox and David Eisenberg and is headquartered in Thousand Oaks, CA. | Corporate Officer/Principal | 01/09/2021 | - |
Historique de carrière de Ana Radeljevic
Anciens postes connus de Ana Radeljevic
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| REVVITY, INC. | Corporate Officer/Principal | 01/01/2014 | 01/01/2016 |
Formation de Ana Radeljevic
| Syracuse University | Masters Business Admin |
| Old Dominion University | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 6 |
Opérationnelle
| Corporate Officer/Principal | 2 |
| Director/Board Member | 1 |
| Independent Dir/Board Member | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| REVVITY, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Merrimack Pharmaceuticals, Inc.
 Merrimack Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA. | Health Technology |
ADRx, Inc.
ADRx, Inc. Pharmaceuticals: MajorHealth Technology ADRx, Inc. is a biopharmaceutical company. The firm advances drug candidates for Alzhiemer’s disease, systemic amyloidosis and ovarian cancer. The company was founded by Gary Wilcox and David Eisenberg and is headquartered in Thousand Oaks, CA. | Health Technology |
- Bourse
- Insiders
- Ana Radeljevic
- Expérience
